Accretion Nutraveda Ltd (ANL) — shareholding pattern, promoter holding, financials and share price
About Accretion Nutraveda Ltd (ANL)
Accretion Nutraveda Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as ANL and on the BSE under scrip code 544694. Its ISIN is INE1KVQ01019.
Incorporated in 2021, Accretion Nutraveda is engaged in the manufacturing of Ayurvedic and Nutraceutical products in various dosage forms. [1]
Listed peers in Pharmaceuticals: Brooks Laboratories Ltd, Gujarat Inject (Kerala) Ltd, Achyut Healthcare Ltd, Oxygenta Pharmaceutical Ltd, Sanjivani Paranteral Ltd, Accretion Pharmaceuticals Ltd.
Valuation & Returns
At ₹262 a share, Accretion Nutraveda Ltd (ANL) was valued at a price-to-earnings ratio of 37.4x against an industry P/E of 36.41x and a price-to-book of 6.11x on a book value of ₹42.41 per share. Solomo computes return on equity of 14.29% and return on capital employed of 16.99% from filed results.
- P/E
- 37.4x
- Industry P/E
- 36.41x
- P/B
- 6.11x
- EPS (TTM)
- ₹71.91
- Book value / share
- ₹42.41
- ROE
- 14.29%
- ROCE
- 16.99%
- ROA
- 12.01%
- Debt / equity
- 0.12x
- Dividend yield
- 0%
- EBITDA margin
- 20.77%
- 52-week range
- ₹150.1 – ₹300
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Accretion Nutraveda Ltd (ANL) reported revenue of ₹33.6 crore, net profit of ₹5.07 crore and earnings per share of ₹7. That compares with revenue of ₹16 crore and net profit of ₹2.61 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹19.54 crore and net profit ₹2.69 crore (standalone).
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue (₹ cr) | 2.89 | 5.01 | 16 | 33.6 |
| Net profit (₹ cr) | 0.28 | 0.82 | 2.61 | 5.07 |
| EPS (₹) | 7.78 | 22.78 | 53.59 | 7 |
| Measure | 1Y |
|---|---|
| Sales growth | 219.36% |
| Profit growth | 218.29% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 73.48% of Accretion Nutraveda Ltd (ANL) (unchanged from the previous quarter), foreign institutional investors (FII) hold 1.08% and domestic institutional investors (DII) hold 6.1%. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2026.
Largest disclosed public shareholders in Jun 2026: UNICORN FUND 5.69%, DHIRAJBHAI VAGHJIBHAI KORADIYA 1.3%, RADIANT GLOBAL FUND-CLASS B PARTICIPATING SHARES 1.08%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 73.48% | - | 1.08% | 6.1% | 26.52% |
| Mar 2026 | 73.48% | - | 1.08% | 7% | 26.52% |